Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: Experience of a single institute

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2229-2233

  Qi, Wei Xiang ^a   He, Ai Na ^a   Tang, Li Na ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Osteosarcoma; Pirarubicin; Relapse; Treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PIRARUBICIN;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DISEASE COURSE; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; YOUNG ADULT;

EID: 84872800152     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0021-y     Document Type: Article

References (20)

1. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28: 247-63.
2. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, et al. Superior survival in treatment of primary non-metastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10: 498-507.
3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-90.
4. Enneking WF. An abbreviated history of orthopaedic oncology in North America. Clin Orthop Relat Res. 2000;374:l15-124.
5. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341(5): 342-52.
6. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12: 1849-58.
7. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose response and schedule dependence. J Clin Oncol. 1997;15:2378-84.
8. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer. 2004;42: 320-4.
9. Seibel NL, Krailo M, Chen Z, Healey J, Breitfeld PP, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer. 2007;109: 1646-53.
10. Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, et al. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol. 2004;26:764-7.
11. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors. A children's oncology group study. Pediatr Blood Cancer. 2008;50:254-8.
12. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, et al. Temozolamide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer. 2006;47:30-6.
13. Zou HY, Wu HL, Zhang Y, Li SF, Nie JF, et al. Studying the interaction of pirarubicin with DNA and determining pirarubicin in human urine samples: combining excitation-emission fluorescence matrices with second-order calibration methods. J Fluoresc. 2009;19:955-66.
14. Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, et al. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma. Cancer. 1992;70:1591-7.
15. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107-14.
16. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother. 2002;36:996-9.
17. Zhao H, Yao Y, Wang Z, Lin F, Sun Y, et al. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother. 2010;22:119-24.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
19. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419-25.
20. Berger M, Grignani G, Ferrari S, Biasin E, Brach del Prever A, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009;115:2980-7.